Form 4: Sangamo Therapeutics Executive Sells Shares

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, Inc., reported a sale of common stock on April 22, 2026.

Summary

• Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, Inc., sold 69,827 shares of common stock on April 22, 2026.
• The sale was executed at a weighted-average price of $0.2534 per share, with individual transactions ranging from $0.2533 to $0.2568.
• Following this transaction, Mr. Davis beneficially owns 115,284 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, which can sometimes be interpreted as a bearish signal, although the reasons for the sale are not disclosed.

Negatives

• An executive of Sangamo Therapeutics sold a significant number of shares, which could be perceived negatively by the market.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings typically report transactions by company insiders. Such sales can sometimes signal a lack of confidence in future stock performance, though they can also be for personal financial planning reasons.

Stakeholder Impact

• Shareholders may view the executive's sale of shares with concern, potentially impacting investor sentiment.
• Employees holding stock options or shares may be influenced by the insider's transaction.

Key Dates

Recommendation

The filing reports an insider sale, which is a common event and does not provide sufficient information to warrant a strong buy or sell recommendation. A 'hold' recommendation is appropriate pending further company news or financial disclosures.

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Trading, Stock Sale, Gregory D. Davis, Beneficial Ownership